Tempus AI, Inc. (TEM) Stock Analysis and Metrics

Tempus AI

NASDAQ: TEM

$42.69 ▼ -3.32 (-7.22%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap8.23 Mn

P/E-0.03

P/S0.01

Div. Yield0.00

Total Debt (Qtr)204.62 Mn

Revenue Growth (1y) (Qtr)36.12

Add ratio to table…

About

Tempus AI Inc is a technology company that focuses on healthcare by creating intelligent diagnostics through the application of artificial intelligence in medicine. The company builds a platform that connects laboratory results with patient clinical data to personalize test results and guide treatment decisions. Its core activities include operating high throughput laboratories that perform genomic and molecular testing and developing software tools that integrate multi modal data for research and clinical use.

The company generates revenue primarily from two sources. First it provides diagnostic testing services to hospitals physicians and other healthcare providers and bills insurance or patients directly. Second it licenses de identified data and offers software and analytics services to pharmaceutical and biotechnology companies through its data and applications product line. Revenue also comes from contracts for clinical trial matching and other research services.

The company operates through the following segments: Diagnostics and Data and applications.

• The Diagnostics segment operates the company’s laboratory network that conducts next generation sequencing polymerase chain reaction and other molecular pathology tests for oncology hereditary neuropsychiatry and cardiology patients. It links each test result to the patient’s clinical history including treatment outcomes and adverse events to create personalized reports that improve therapeutic decision making. The segment sells its services to hospitals physicians genetic counselors and also to pharmaceutical firms that use the tests as companion diagnostics or for research.

• The Data and applications segment licenses de identified clinical molecular and imaging data to drug developers and provides software tools such as Hub Lens and Notebooks for data analysis. It also offers applications that use artificial intelligence to match patients to clinical trials to identify care gaps and to generate algorithmic diagnostics for oncology cardiology and other diseases. Revenue is generated through data licensing agreements subscription fees and service contracts with biopharma companies.

Tempus holds a distinctive position in the precision medicine market due to its ability to combine large scale laboratory testing with a proprietary data platform that links molecular results to real world clinical information. Its main competitors in diagnostics include Foundation Medicine Caris Life Sciences Guardant Health Natera and Quest Diagnostics. In the data and services arena it competes with Flatiron Health IQVIA ConcertAI and various contract research organizations. The company’s competitive advantage stems from its network effects where each additional data point improves the accuracy of its tests and the value of its database making it harder for rivals to replicate.

The company serves a broad range of customers including hospitals physician groups academic medical centers and pathology laboratories that order its diagnostic tests. It also works with nineteen of the twenty largest public pharmaceutical companies and has strategic collaborations with firms such as AstraZeneca GlaxoSmithKline and Recursion Pharmaceuticals. Additionally its data and analytics products are used by biotechnology firms research institutions and contract research organizations seeking to access its curated multimodal database.

Investment Thesis

▲ Bull case

Tempus AI is positioned to capitalize on the structural shift toward AI-integrated precision medicine, as evidenced by the recent launch of its next-generation generative AI clinical co-pilot within Tempus Hub, which directly connects agentic AI capabilities with real-time patient data to unlock decision support at the point of care. This upgrade leverages the company’s foundational investments in Edge, Locker, and Air infrastructure—enabling real-time EHR connectivity, secure data storage, and GPU-accelerated model deployment—creating a defensible moat that competitors cannot easily replicate. The platform’s ability to provide seamless access to guideline-matched therapies, treatment resistance insights, and longitudinal biomarker tracking transforms diagnostic results into actionable clinical workflows, addressing a critical unmet need in oncology care delivery. Management’s emphasis on this being a “massive win for clinical workflow efficiency” signals that adoption will accelerate as providers recognize tangible time savings and improved decision confidence, driving stickiness and expansion within existing accounts while attracting new health systems seeking to modernize their oncology workflows. This initiative is not merely an incremental feature but a strategic evolution that aligns with the broader industry trend toward AI-augmented clinical decision support, positioning Tempus as an indispensable partner in the modern oncology ecosystem.
The company’s data licensing and modeling business is experiencing accelerated growth and durability, underscored by the recent FDA approval of the tumor-only indication for its xT CDx assay, which eliminates the need for matched normal samples and enables migration of the entire solid tumor DNA portfolio to unified ADLT pricing. As noted by the CFO, this regulatory milestone is expected to deliver an estimated $200 ASP benefit beginning in 2027, directly improving unit economics and margin expansion in the diagnostics segment. This approval, combined with the over 500 petabytes of de-identified, linked clinical and molecular data now supporting large-scale analytics and model-building on both CPUs and GPUs, creates a powerful feedback loop: more data fuels better models, which drive higher algorithm attach rates (currently ~40% for oncology solid tumor assays) and increased ASP through FDA-approved assays like XT and XF. The strategic collaborations with Merck and Gilead—described as “very large, multi-year” and a “substantial step up” from historic levels—further validate the durability and scalability of Tempus’ data business, with management highlighting that these agreements reflect a migration where pharma is not just licensing data but actively building models with Tempus, ensuring long-term, sticky relationships that extend well beyond 2026.
Tempus is successfully diversifying beyond its core oncology foundation into adjacent high-growth areas, creating new revenue streams that reduce concentration risk and unlock multi-billion-dollar opportunities. The ongoing multimillion-dollar Alzheimer’s disease modeling project in neurology, combined with the Lucent Diagnostics collaboration to integrate the LucentAD Complete blood-based biomarker panel into Tempus Next for Alzheimer’s care gap identification, demonstrates tangible traction in neurology—a market with over 7 million Americans living with Alzheimer’s disease yet only a small fraction evaluated for approved therapies. Similarly, the recent launch of the xH assay for hematologic malignancies, which uncovered 40% more clinically relevant genomic findings than standard of care in an MDS cohort, addresses a critical diagnostic blind spot in blood cancers. These initiatives are not speculative; they are backed by real-world validation studies, ASCO presentations, and active commercial rollout plans. Management’s assertion that the data and modeling business can reach “multi-billions of dollars” in the U.S. alone, let alone internationally, is grounded in these expansion efforts, which leverage the same foundational multimodal data and AI infrastructure that powers its oncology leadership, allowing for rapid, low-cost entry into new disease areas with significant ASP accretion potential.
The company’s financial trajectory is underpinned by improving unit economics and operational leverage, with management explicitly stating they “do not need more cash” and projecting no requirement for alternative financings to support operational plans. Adjusted EBITDA improved over $13 million year-over-year in Q1 FY26, with further sequential expansion expected driven by favorable margin timing and increased data revenue in the latter half of the year. The shift in Insights contract payment structures from prepayments burning down to quarterly payments, combined with normalization of payables, is expected to drive significant cash flow improvement in Q2 FY26 and beyond. Meanwhile, the ASP sits at $17.20–$17.40 with potential for a $500 increase over the next one to two years as more assays gain FDA approval—directly tied to the xT CDx tumor-only approval and pending XF and XT amendments. This pricing power, coupled with rising algorithm attach rates (e.g., homologous recombination deficiency and immune profile scores) and early-to-middle adoption phases in oncology therapy selection, creates a clear path to margin expansion without relying on volume alone. The $350 million TCV linked to 2026 revenue, now augmented by Merck and Gilead deals, provides exceptional visibility, while the continued TCV growth despite large revenue recognition in Q1 FY26 signals a robust, self-replenishing pipeline that de-risks near-term guidance.
Tempus’ competitive advantage is reinforced by its unique integration of diagnostics, data, and AI under a single platform, creating a flywheel effect where every diagnostic test generates data that improves AI models, which in turn enhances diagnostic accuracy and clinical utility—thereby driving more test volume. This is exemplified by the Tempus Preview application, which delivers clinically significant insights within 24 hours of tissue receipt by leveraging multimodal data and advanced AI on early workflow touchpoints, directly addressing the critical information gap between test order and final sequencing results. The integration of externally developed algorithms like the ArteraAI Prostate Test (mHSPC) into the Tempus ecosystem further strengthens this flywheel, allowing the company to rapidly incorporate breakthrough innovations without internal R&D bottlenecks. As Eric Lefkofsky noted, “every insight strengthens our models, and every model helps generate more clinically meaningful insights,” creating a self-reinforcing cycle that competitors relying on siloed data or standalone AI tools cannot replicate. This end-to-end control—from sample to insight to action—positions Tempus not just as a vendor but as an essential infrastructure provider in the precision medicine value chain, with switching costs rising as providers embed its tools into their clinical workflows.

Tempus AI is positioned to capitalize on the structural shift toward AI-integrated precision medicine, as evidenced by the recent launch of its next-generation generative AI clinical co-pilot within Tempus Hub, which directly connects agentic AI capabilities with real-time patient data to unlock decision support at the point of care. This upgrade leverages the company’s foundational investments in Edge, Locker, and Air infrastructure—enabling real-time EHR connectivity, secure data storage, and GPU-accelerated model deployment—creating a defensible moat that competitors cannot easily replicate. The platform’s ability to provide seamless access to guideline-matched therapies, treatment resistance insights, and longitudinal biomarker tracking transforms diagnostic results into actionable clinical workflows, addressing a critical unmet need in oncology care delivery. Management’s emphasis on this being a “massive win for clinical workflow efficiency” signals that adoption will accelerate as providers recognize tangible time savings and improved decision confidence, driving stickiness and expansion within existing accounts while attracting new health systems seeking to modernize their oncology workflows. This initiative is not merely an incremental feature but a strategic evolution that aligns with the broader industry trend toward AI-augmented clinical decision support, positioning Tempus as an indispensable partner in the modern oncology ecosystem.
The company’s data licensing and modeling business is experiencing accelerated growth and durability, underscored by the recent FDA approval of the tumor-only indication for its xT CDx assay, which eliminates the need for matched normal samples and enables migration of the entire solid tumor DNA portfolio to unified ADLT pricing. As noted by the CFO, this regulatory milestone is expected to deliver an estimated $200 ASP benefit beginning in 2027, directly improving unit economics and margin expansion in the diagnostics segment. This approval, combined with the over 500 petabytes of de-identified, linked clinical and molecular data now supporting large-scale analytics and model-building on both CPUs and GPUs, creates a powerful feedback loop: more data fuels better models, which drive higher algorithm attach rates (currently ~40% for oncology solid tumor assays) and increased ASP through FDA-approved assays like XT and XF. The strategic collaborations with Merck and Gilead—described as “very large, multi-year” and a “substantial step up” from historic levels—further validate the durability and scalability of Tempus’ data business, with management highlighting that these agreements reflect a migration where pharma is not just licensing data but actively building models with Tempus, ensuring long-term, sticky relationships that extend well beyond 2026.
Tempus is successfully diversifying beyond its core oncology foundation into adjacent high-growth areas, creating new revenue streams that reduce concentration risk and unlock multi-billion-dollar opportunities. The ongoing multimillion-dollar Alzheimer’s disease modeling project in neurology, combined with the Lucent Diagnostics collaboration to integrate the LucentAD Complete blood-based biomarker panel into Tempus Next for Alzheimer’s care gap identification, demonstrates tangible traction in neurology—a market with over 7 million Americans living with Alzheimer’s disease yet only a small fraction evaluated for approved therapies. Similarly, the recent launch of the xH assay for hematologic malignancies, which uncovered 40% more clinically relevant genomic findings than standard of care in an MDS cohort, addresses a critical diagnostic blind spot in blood cancers. These initiatives are not speculative; they are backed by real-world validation studies, ASCO presentations, and active commercial rollout plans. Management’s assertion that the data and modeling business can reach “multi-billions of dollars” in the U.S. alone, let alone internationally, is grounded in these expansion efforts, which leverage the same foundational multimodal data and AI infrastructure that powers its oncology leadership, allowing for rapid, low-cost entry into new disease areas with significant ASP accretion potential.
The company’s financial trajectory is underpinned by improving unit economics and operational leverage, with management explicitly stating they “do not need more cash” and projecting no requirement for alternative financings to support operational plans. Adjusted EBITDA improved over $13 million year-over-year in Q1 FY26, with further sequential expansion expected driven by favorable margin timing and increased data revenue in the latter half of the year. The shift in Insights contract payment structures from prepayments burning down to quarterly payments, combined with normalization of payables, is expected to drive significant cash flow improvement in Q2 FY26 and beyond. Meanwhile, the ASP sits at $17.20–$17.40 with potential for a $500 increase over the next one to two years as more assays gain FDA approval—directly tied to the xT CDx tumor-only approval and pending XF and XT amendments. This pricing power, coupled with rising algorithm attach rates (e.g., homologous recombination deficiency and immune profile scores) and early-to-middle adoption phases in oncology therapy selection, creates a clear path to margin expansion without relying on volume alone. The $350 million TCV linked to 2026 revenue, now augmented by Merck and Gilead deals, provides exceptional visibility, while the continued TCV growth despite large revenue recognition in Q1 FY26 signals a robust, self-replenishing pipeline that de-risks near-term guidance.
Tempus’ competitive advantage is reinforced by its unique integration of diagnostics, data, and AI under a single platform, creating a flywheel effect where every diagnostic test generates data that improves AI models, which in turn enhances diagnostic accuracy and clinical utility—thereby driving more test volume. This is exemplified by the Tempus Preview application, which delivers clinically significant insights within 24 hours of tissue receipt by leveraging multimodal data and advanced AI on early workflow touchpoints, directly addressing the critical information gap between test order and final sequencing results. The integration of externally developed algorithms like the ArteraAI Prostate Test (mHSPC) into the Tempus ecosystem further strengthens this flywheel, allowing the company to rapidly incorporate breakthrough innovations without internal R&D bottlenecks. As Eric Lefkofsky noted, “every insight strengthens our models, and every model helps generate more clinically meaningful insights,” creating a self-reinforcing cycle that competitors relying on siloed data or standalone AI tools cannot replicate. This end-to-end control—from sample to insight to action—positions Tempus not just as a vendor but as an essential infrastructure provider in the precision medicine value chain, with switching costs rising as providers embed its tools into their clinical workflows.

▼ Bear case

Despite strong revenue growth, Tempus AI faces significant and underappreciated pressure on its path to profitability, as evidenced by the Q1 FY26 cash flow from operations declining approximately $70 million due to typical seasonal outflows including bonuses and timing of payables—a recurring pattern that management acknowledges will normalize in Q2 but raises concerns about the sustainability of cash generation if working capital dynamics deteriorate. The company’s reliance on large, upfront payments from Insights contracts (which burn down over time) creates a misleading impression of cash flow strength; when these prepayments roll off and are not replaced by equivalent new bookings, operating cash flow could face renewed pressure. Furthermore, the admission that “if we were to 10x our MRD volume tomorrow, our cash burn would go up a lot” reveals a fundamental tension: while MRD growth is explosive (500% YoY), its unit economics remain challenged until reimbursement improves, meaning aggressive volume expansion in this high-potential area would directly worsen cash flow and EBITDA in the near term. This creates a strategic dilemma where pursuing growth in MRD—cited as a key long-term lever—could undermine the very profitability metrics management is guiding toward, forcing a trade-off between top-line expansion and bottom-line health that is not being adequately communicated to investors.
The durability of Tempus’ data licensing business is overstated, as management’s emphasis on “strong core big data relationships” and “robust renewal history” obscures growing risks from evolving data privacy regulations, AI-specific compliance burdens, and the potential for large pharma to develop internal data capabilities that reduce reliance on third-party providers. While the company highlights its 500+ petabyte database and GPU-enabled analytics platform, the increasing scrutiny around de-identified data usage in AI training—particularly under evolving regulations in the artificial intelligence space—could impose unexpected costs or restrictions on how Tempus monetizes its data, especially if future regulations require explicit patient consent for secondary use of clinical data in model building. Additionally, the shift toward pharma building “foundation models” with Tempus’ data (as seen with AstraZeneca) suggests a trajectory where partners may eventually internalize model development, reducing long-term licensing dependency. The reliance on a few mega-deals (e.g., Merck, Gilead) also introduces concentration risk; if any of these strategic collaborations face delays, scope reductions, or non-renewal due to shifting pharma priorities or internal AI investments, the Insights segment’s growth could decelerate sharply, contradicting the narrative of durable, multi-billion-dollar potential.
Tempus’ ASP expansion thesis is overly optimistic and contingent on uncertain regulatory and reimbursement timelines, particularly regarding the XF assay and the broader migration to ADLT pricing. While the tumor-only approval for xT CDx is expected to deliver a $200 ASP benefit beginning in 2027, the XF FDA submission remains without feedback, and the amendment for a tumor-only version of XT is only “pending a near-term regulatory decision”—with no guarantee of approval or timing. The current ASP of $17.20–$17.40 is far below the implied $500+ potential, and achieving such a leap requires multiple assays to gain FDA approval and secure ADLT status, a process historically subject to delays, additional data requests, or rejections. Moreover, the company’s admission that rare disease testing will “not meaningfully shift unit volume” despite ASP accretion highlights the limits of pricing power in low-volume segments; even if ASP increases, the hereditary testing segment’s mid-teens growth projection (dependent on lapping prior-year extremes) suggests limited upside from volume, leaving the business overly reliant on data licensing for growth—a segment that, as noted, faces its own headwinds from regulatory and competitive pressures. Without near-term catalysts to drive ASP expansion, the 2026 guidance of $65 million in adjusted EBITDA may prove aggressive if data licensing growth slows or diagnostics ASP fails to inflect as expected.
The company’s expansion into adjacent areas like neurology and hematology, while promising, remains nascent and unproven at scale, with significant execution risks that could divert resources from core oncology without delivering proportional returns. The Alzheimer’s disease modeling project is described as a “multimillion-dollar” initiative finishing mid-year, but there is no disclosure of revenue contribution, customer concentration, or path to commercialization beyond the research phase. Similarly, the Lucent Diagnostics collaboration for Alzheimer’s blood-based biomarker testing depends on neurologists adopting the LucentAD Complete test through Tempus Next—a behavioral change that requires overcoming entrenched workflows, reimbursement hurdles, and clinician education barriers, all of which are unquantified in the disclosures. The xH assay for hematologic malignancies, while showing >99% sensitivity in an MDS cohort, is still pending commercial availability “later this year,” with no clarity on pricing, reimbursement pathways, or adoption rates among hematologists. These initiatives represent strategic bets that, if unsuccessful, could result in sunk costs without offsetting gains, particularly given the company’s acknowledgment that it is “not unleashing” its full sales force on MRD due to unit economics concerns—suggesting a broader pattern of cautious rollout in new areas that may limit upside potential while still incurring fixed costs for development, regulatory, and sales support.
Tempus’ guidance for 25% top-line growth over the next three years assumes continued strength in both diagnostics and data segments, yet overlooks the increasing competitive intensity in oncology diagnostics from both established players (e.g., Foundation Medicine, Guardant Health) and new entrants leveraging AI and liquid biopsy innovations, which could erode market share or force pricing concessions. The management’s dismissal of companion diagnostic (CDx) impacts—stating CDXs “have had no impact on physician ordering in the U.S.”—may be shortsighted, as the growing formal integration of biomarker testing into drug labels (e.g., for Erbitux/Vectibix with xT CDx) could eventually shift reimbursement dynamics or create payer preferences for specific assays, especially if CMS or commercial payers begin to preferentially cover tests with CDx status. Furthermore, the reliance on therapy selection as a growth engine assumes sustained industry-wide adoption of comprehensive genomic profiling, but if reimbursement policies tighten or alternative diagnostics (e.g., AI-driven histopathology tools like Tempus Preview or Paige Predict) gain traction without requiring NGS, the demand for Tempus’ core solid tumor and liquid biopsy assays could plateau faster than anticipated. The business model’s sensitivity to macroeconomic factors—such as hospital budget cuts, payer reimbursement delays, or reduced pharma R&D spending—is not adequately stressed in the guidance, leaving investors exposed to downside scenarios where growth decelerates not due to execution failure but to external industry headwinds that are more structural than temporary.

Despite strong revenue growth, Tempus AI faces significant and underappreciated pressure on its path to profitability, as evidenced by the Q1 FY26 cash flow from operations declining approximately $70 million due to typical seasonal outflows including bonuses and timing of payables—a recurring pattern that management acknowledges will normalize in Q2 but raises concerns about the sustainability of cash generation if working capital dynamics deteriorate. The company’s reliance on large, upfront payments from Insights contracts (which burn down over time) creates a misleading impression of cash flow strength; when these prepayments roll off and are not replaced by equivalent new bookings, operating cash flow could face renewed pressure. Furthermore, the admission that “if we were to 10x our MRD volume tomorrow, our cash burn would go up a lot” reveals a fundamental tension: while MRD growth is explosive (500% YoY), its unit economics remain challenged until reimbursement improves, meaning aggressive volume expansion in this high-potential area would directly worsen cash flow and EBITDA in the near term. This creates a strategic dilemma where pursuing growth in MRD—cited as a key long-term lever—could undermine the very profitability metrics management is guiding toward, forcing a trade-off between top-line expansion and bottom-line health that is not being adequately communicated to investors.
The durability of Tempus’ data licensing business is overstated, as management’s emphasis on “strong core big data relationships” and “robust renewal history” obscures growing risks from evolving data privacy regulations, AI-specific compliance burdens, and the potential for large pharma to develop internal data capabilities that reduce reliance on third-party providers. While the company highlights its 500+ petabyte database and GPU-enabled analytics platform, the increasing scrutiny around de-identified data usage in AI training—particularly under evolving regulations in the artificial intelligence space—could impose unexpected costs or restrictions on how Tempus monetizes its data, especially if future regulations require explicit patient consent for secondary use of clinical data in model building. Additionally, the shift toward pharma building “foundation models” with Tempus’ data (as seen with AstraZeneca) suggests a trajectory where partners may eventually internalize model development, reducing long-term licensing dependency. The reliance on a few mega-deals (e.g., Merck, Gilead) also introduces concentration risk; if any of these strategic collaborations face delays, scope reductions, or non-renewal due to shifting pharma priorities or internal AI investments, the Insights segment’s growth could decelerate sharply, contradicting the narrative of durable, multi-billion-dollar potential.
Tempus’ ASP expansion thesis is overly optimistic and contingent on uncertain regulatory and reimbursement timelines, particularly regarding the XF assay and the broader migration to ADLT pricing. While the tumor-only approval for xT CDx is expected to deliver a $200 ASP benefit beginning in 2027, the XF FDA submission remains without feedback, and the amendment for a tumor-only version of XT is only “pending a near-term regulatory decision”—with no guarantee of approval or timing. The current ASP of $17.20–$17.40 is far below the implied $500+ potential, and achieving such a leap requires multiple assays to gain FDA approval and secure ADLT status, a process historically subject to delays, additional data requests, or rejections. Moreover, the company’s admission that rare disease testing will “not meaningfully shift unit volume” despite ASP accretion highlights the limits of pricing power in low-volume segments; even if ASP increases, the hereditary testing segment’s mid-teens growth projection (dependent on lapping prior-year extremes) suggests limited upside from volume, leaving the business overly reliant on data licensing for growth—a segment that, as noted, faces its own headwinds from regulatory and competitive pressures. Without near-term catalysts to drive ASP expansion, the 2026 guidance of $65 million in adjusted EBITDA may prove aggressive if data licensing growth slows or diagnostics ASP fails to inflect as expected.
The company’s expansion into adjacent areas like neurology and hematology, while promising, remains nascent and unproven at scale, with significant execution risks that could divert resources from core oncology without delivering proportional returns. The Alzheimer’s disease modeling project is described as a “multimillion-dollar” initiative finishing mid-year, but there is no disclosure of revenue contribution, customer concentration, or path to commercialization beyond the research phase. Similarly, the Lucent Diagnostics collaboration for Alzheimer’s blood-based biomarker testing depends on neurologists adopting the LucentAD Complete test through Tempus Next—a behavioral change that requires overcoming entrenched workflows, reimbursement hurdles, and clinician education barriers, all of which are unquantified in the disclosures. The xH assay for hematologic malignancies, while showing >99% sensitivity in an MDS cohort, is still pending commercial availability “later this year,” with no clarity on pricing, reimbursement pathways, or adoption rates among hematologists. These initiatives represent strategic bets that, if unsuccessful, could result in sunk costs without offsetting gains, particularly given the company’s acknowledgment that it is “not unleashing” its full sales force on MRD due to unit economics concerns—suggesting a broader pattern of cautious rollout in new areas that may limit upside potential while still incurring fixed costs for development, regulatory, and sales support.
Tempus’ guidance for 25% top-line growth over the next three years assumes continued strength in both diagnostics and data segments, yet overlooks the increasing competitive intensity in oncology diagnostics from both established players (e.g., Foundation Medicine, Guardant Health) and new entrants leveraging AI and liquid biopsy innovations, which could erode market share or force pricing concessions. The management’s dismissal of companion diagnostic (CDx) impacts—stating CDXs “have had no impact on physician ordering in the U.S.”—may be shortsighted, as the growing formal integration of biomarker testing into drug labels (e.g., for Erbitux/Vectibix with xT CDx) could eventually shift reimbursement dynamics or create payer preferences for specific assays, especially if CMS or commercial payers begin to preferentially cover tests with CDx status. Furthermore, the reliance on therapy selection as a growth engine assumes sustained industry-wide adoption of comprehensive genomic profiling, but if reimbursement policies tighten or alternative diagnostics (e.g., AI-driven histopathology tools like Tempus Preview or Paige Predict) gain traction without requiring NGS, the demand for Tempus’ core solid tumor and liquid biopsy assays could plateau faster than anticipated. The business model’s sensitivity to macroeconomic factors—such as hospital budget cuts, payer reimbursement delays, or reduced pharma R&D spending—is not adequately stressed in the guidance, leaving investors exposed to downside scenarios where growth decelerates not due to execution failure but to external industry headwinds that are more structural than temporary.

Period. Breakdown of Revenue (2026)

Peer Comparison

Companies in the Health Information Services

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	VEEV	Veeva Systems Inc	29.34 Bn	31.16	8.84	-
2	BTSG	BrightSpring Health Services, Inc.	13.49 Bn	46.18	0.99	2.50 Bn
3	HQY	Healthequity, Inc.	7.96 Bn	34.51	5.95	0.94 Bn
4	TXG	10x Genomics, Inc.	6.17 Bn	-272.14	9.65	-
5	HNGE	Hinge Health, Inc.	6.02 Bn	-11.77	9.31	-
6	MMED	MiniMed Group, Inc.	4.19 Bn	-8.88	1.38	-
7	WAY	Waystar Holding Corp.	4.14 Bn	32.80	3.58	1.47 Bn
8	DOCS	Doximity, Inc.	3.82 Bn	19.51	5.93	-

Research Tools

Developers

About

Investment Thesis

Period. Breakdown of Revenue (2026)

Period. Breakdown of Revenue (2026)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Period. Breakdown of Revenue (2026)

Period. Breakdown of Revenue (2026)

Peer Comparison

Create an account

Sign In

Reset Password